Physician profile
Owolabi Ogunneye
NPI 1992011472
$4,084.05
in general payments reported to CMS, 2019-2025
24 companies · $884 in 2025
The $884 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $62.16 · 2021: $1,678 · 2022: $258 · 2023: $324 · 2024: $606 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,698 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,698.38 |
| Education | $115.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,622.17 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $265.12 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $219.11 | 2022-2025 | Tarpeyo |
| Amgen INC. | $206.32 | 2019-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $198.68 | 2019-2022 | |
| Travere Therapeutics, INC. | $193.03 | 2023-2025 | |
| Recor Medical INC | $176.92 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Apellis Pharmaceuticals, INC. | $158.68 | 2025 | Empaveli |
| Fresenius USA Marketing, INC. | $149.84 | 2022-2024 | Velphoro, Nxstage System One, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $119.15 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $101.81 | 2023-2024 | Rayaldee |
| Scpharmaceuticals INC. | $99.41 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $85.89 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $76.02 | 2022-2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.30 | 2023-2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $56.39 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Enterprises LLC | $55.78 | 2019 | |
| Akebia Therapeutics INC | $54.01 | 2019-2024 | Auryxia, Vafseo |
| Lilly USA, LLC | $44.22 | 2023-2024 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $41.92 | 2020-2021 | |
| Glaxosmithkline, LLC. | $41.13 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $16.62 | 2019 | |
| Alkermes, INC. | $16.12 | 2021 | |
| Ardelyx, INC. | $14.41 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Owolabi Ogunneye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.